Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - Stoke Therapeutics, Inc. | stok-ex321_6.htm |
EX-31.2 - EX-31.2 - Stoke Therapeutics, Inc. | stok-ex312_908.htm |
EX-31.1 - EX-31.1 - Stoke Therapeutics, Inc. | stok-ex311_909.htm |
EX-23.1 - EX-23.1 - Stoke Therapeutics, Inc. | stok-ex231_9.htm |
EX-10.10 - EX-10.10 - Stoke Therapeutics, Inc. | stok-ex1010_829.htm |
EX-10.7 - EX-10.7 - Stoke Therapeutics, Inc. | stok-ex107_828.htm |
EX-4.3 - EX-4.3 - Stoke Therapeutics, Inc. | stok-ex43_1204.htm |
10-K - 10-K - Stoke Therapeutics, Inc. | stok-10k_20201231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Stoke Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: March 9, 2021 |
By: |
/s/ Stephen J. Tulipano, CPA |
|
|
Stephen J. Tulipano |
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |